Effects of candesartan in patients with chronic heart failure: The CHARM-trial;L'étude clinique du mois: L'étude CHARM

Revue Medicale de Liege

Volumn 58, Issue 10, 2003, Pages 646-652

  Kulbertus, H ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b NONE   (Belgium)

Author keywords

AT1 angiotensin receptor blockade; Candesartan; Heart failure; The CHARM trials

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIGITALIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; SPIRONOLACTONE;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG RESPONSE; FOLLOW UP; HEALTH PROGRAM; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MORTALITY; PATIENT; RANDOMIZED CONTROLLED TRIAL; REVIEW; STATISTICAL SIGNIFICANCE; STUDY; SYMPTOMATOLOGY; TITRIMETRY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0345096561     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. http://www.escardio.org.- Site internet de la Société Européenne de Cardiologie.
2. Pfeffer MA, Swedberg K, Granger CB, et al. for the CHARM Investigators and Committees.- Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, 2003, 362, 759-766.
3. Granger CB, McMurray JJ, Yusuf S, et al. for the CHARM Investigators and Committees.- Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM -Alternative trial. Lancet, 2003, 362, 772-776.
4. McMurray JJ, Östergren J, Swedberg K et al for the CHARM Investigators and Committees.- Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet, 2003, 362, 767-771.
5. Yusuf S, Pfeffer MA, Swedberg K et al for the CHARM Investigators and Committees.- Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction:the CHARM-Preserved trial. Lancet, 2003, 362, 777-781.
6. White HD.- Commentary. Candesartan and heart failure:the allure of CHARM. Lancet, 2003, 362, 754-755.
7. Kulbertus H.- Le médicament du mois: le candesartan (Atacand). Rev Méd Liège, 1999, 54, 557-560.
8. Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology:WJ Remme and K Swedberg (Co-chairmen).- Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J, 2001, 22, 1527-1560.
9. Goodfriend TL, Elliott ME, Catt KJ.- Angiotensin receptors and their antagonists. N Eng J Med, 1996, 334, 1649-1655.
10. McKelvie RS, Yusuf S, Pericak D for the RESOLVD Pilot Study Investigators.- Comparison of candesartan, enalapril and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation, 1999, 100, 1056-1064.
11. Baruch L, Anand I, Cohen IS et al. for the Vasodilatator Heart Failure Trial (V-HeFT) study Group.- Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation, 1999, 99, 2658-2664.
12. Cohn JN, Tognoni GA.- A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med, 2001, 345, 1667-1675.
13. Hunt SA, Baker DW, Chin MH et al.- ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2001, 104, 2996-3007.
14. Yusuf S, Gerstein H, Hoogwerf B et al.- Ramipril and the development of diabetes. JAMA, 2001, 286, 1882-1885.
15. Dahlof B, Devereux RB, Kjeldsen SE et al for the LIFE Study Group.- Cardiovascular mortality and morbidity in the Losartan Intarevention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet, 2002, 359, 995-1003.
16. Sakata Y, Yamamoto K, Mono T, et al.- Angiotensine II type 1 receptor blockade prevents diastolic heart failure through modulation of Ca2+ regulatory proteins and extracellular matrix, J Hypertension, 2003, 21, 1737-1745.